Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.55 +0.47%

+$0.16 today

Market cap
$2.16B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.68M

Average 0.94M

CLDX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $62.93M a year earlier. Trailing-twelve-month cost of revenue was $854K.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, down 2329.8 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $213.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$854K-99.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 cost of revenue of $854K is the 7th highest of the 10 companies compared; the peer median is $8.68M.
  • Its year-over-year change of -99.5% is the lowest of 7, against a peer median of -37.0%.
  • Cost of revenue amounts to 762.5% of revenue for CLDX, versus a peer median of 30.1%.
CLDX Competitors Peer median
Cost of Revenue for CLDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M -56.9%-53.2%13.5%
XNCRXencor, Inc.LTM Jun 2026$59.51M -6.4%-62.5%56.7%
AGENAgenus Inc.LTM Mar 2026$59.29M -55.6%-25.9%47.9%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M -18.4%+80.2%30.1%
CGENCompugen Ltd.LTM Mar 2026$8.68M +5.4%+111.7%11.9%
RCUSArcus Biosciences, Inc.LTM Jun 2026$7M ——6.0%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$854K -99.5%—762.5%
IMNMImmunome, Inc.LTM Sep 2026$753K -98.5%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026$738K ———
ADAGAdagene Inc.LTM Jun 2024$425.46K ——52.2%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CLDX) $8.68M-37.0%-25.9%30.1%

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$27.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.